Served as Vice President of Global Manufacturing; Executive Vice President of Global Commercial & Technical Operations at Biogen Idec Ltd; Chief Executive Officer of Bioverativ (Hemophilia Company)
John Cox was the CEO of Bioverativ. He led the Bioverativ spin-off from Biogen and grew the company from a new venture with two drugs, Eloctate® and Alprolix® for the treatment of hemophilia A and B, into a global company with a significant pipeline, nearly 500 employees and over $1.1B in sales. He built, grew, and led company to successful acquisition by Sanofi in February of 2018 for $11.6B, creating $7B in shareholder value in 12 months.
John currently serves as Executive Chairman of Torque Therapeutics, a cellular immuno-oncology early stage company. He is also the Chairman of Minovia, a privately held mitochondrial cell therapeutics company, and he serves on the board of directors for Repligen Corporation, a publicly held bioprocessing supplier.
Previously, John was Executive Vice President, Global Commercial & Technical Operations at Biogen. He was a member of the executive leadership team and was globally responsible for all aspects of an $10B commercial operation, as well as technical development and all drug supply, directing roughly 2/3rds of Biogen’s 8000 employees and financial budgets.
John brings over 25 years of experience in biopharmaceuticals with roles of increasing responsibility at Biogen. Cox was Executive Vice President of Pharmaceutical Operations & Technology where he oversaw the company’s production facilities, supply chain operations, technical development, quality and engineering across the globe. He also had responsibility for the creation of the company’s biosimilar business, including its successful commercialization in Europe.
Before joining Biogen Idec in 2003, John held a number of senior operational roles with biotech contract manufacturer Covance/Diosynth, where he led teams engaged in technology transfer, validation and purification. Prior to that, he held positions of increasing responsibility in similar areas with vaccine-maker Wyeth Corp.
John holds an MBA from the University of Michigan, an MS in Cell Biology from California State University and a BS in Biology from Arizona State University
Ph.D. in Biochemistry at The Hebrew University; Postdoctoral fellowship at the Weizmann Institute; Twenty years experience in mitochondrial research
General Manager of Soreq Nuclear Center, Israel, 1990-1998; Co-founded 6 successful hi-tech companies: Opal, X-Technologies, Kailight, Radiancy, Sonotron and Oplon; Serial entrepreneur and inventor
Has vast experience in brokerage and investment banking as the former Chief Executive Officer and Partner at I. B. I. Investment Banking. Angel investor and member of the board of several companies